Biotech Values

[DewDiligence]

VNDA starts phase-3 trial_of Nereus to_reduce GLP-1-induced nausea/vomiting:

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-initiation-of-the-thetis-study-a-clinical-trial-of-nereus-for-the-prevention-of-vomiting-induced-by-glp-1-receptor-agonists-302737472.html

The FDA approved Nereus for motion sickness In Dec 2025.